JGP Global Gestao de Recursos Ltda. grew its position in argenx SE – (NASDAQ:ARGX) by 9.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,288 shares of the company’s stock after acquiring an additional 188 shares during the quarter. JGP Global Gestao de Recursos Ltda.’s holdings in argenx were worth $286,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also recently added to or reduced their stakes in ARGX. We Are One Seven LLC bought a new stake in argenx in the 4th quarter worth approximately $27,000. Partner Investment Management L.P. bought a new stake in argenx in the 4th quarter worth approximately $110,000. Brown Advisory Securities LLC bought a new stake in argenx in the 4th quarter worth approximately $217,000. Virtu Financial LLC bought a new stake in argenx in the 1st quarter worth approximately $217,000. Finally, Townsquare Capital LLC bought a new stake in argenx in the 4th quarter worth approximately $273,000. 63.72% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms have issued reports on ARGX. ValuEngine raised argenx from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Guggenheim began coverage on argenx in a research note on Friday, February 22nd. They issued a “buy” rating and a $157.00 price objective on the stock. Zacks Investment Research downgraded argenx from a “hold” rating to a “sell” rating in a research note on Tuesday, March 5th. Wedbush lifted their price objective on argenx from $131.00 to $144.00 and gave the stock an “outperform” rating in a research note on Friday, March 1st. Finally, SunTrust Banks reissued a “buy” rating on shares of argenx in a research report on Friday, January 18th. One equities research analyst has rated the stock with a sell rating and thirteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $140.91.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Featured Story: Dividend Aristocrat Index
Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE – (NASDAQ:ARGX).
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.